Urban-rural disparities of cancer patients with first-time hospice care from 2000–2006.

<p>Urban-rural disparities of cancer patients with first-time hospice care from 2000–2006.</p

Hospice resources and utilization from 2000–2006.

<p>Hospice resources and utilization from 2000–2006.</p

Features of cancer patients with hospice care during 2000–2006, stratified by location of residence.

<p>Features of cancer patients with hospice care during 2000–2006, stratified by location of residence.</p

Clinic visit-level bivariate analysis (N = 605239) according to the three sets of potentially inappropriate medication criteria.

<p>Abbreviations: MD- Medical Doctor, NTD- New Taiwan dollar.</p><p>***<i>P</i><0.001.</p

Characteristics of the three sets of explicit criteria and their performance in detecting potentially inappropriate medications.

<p>*Statements are those for potentially inappropriate medications without considering drug-disease or drug-syndrome interactions.</p

Multivariate logistic regression for having at least one potentially inappropriate medication in one clinic visit.

<p>***<i>P</i><0.0001.</p

Multivariate logistic regression for having at least one drug as potentially inappropriate.

<p>*<i>P</i><0.05,</p><p>**<i>P</i><0.01,</p><p>***<i>P</i><0.001.</p

Basic characteristics of the home healthcare recipients.

<p>Basic characteristics of the home healthcare recipients.</p

Patient-level bivariate analysis (N = 25187) by the presence of least one PIM according to the three sets of potentially inappropriate medication criteria.

<p>***<i>P</i><0.0001.</p

The leading ten potentially inappropriate medications (PIMs) identified in 2,428,222 prescribed medications.

<p>Beers criteria- 2012 version of Beers criteria, PIM-Taiwan criteria- potentially inappropriate medication Taiwan criteria.</p><p>*Zolpidem is considered as PIMs if daily dose is more than 5 mg in PRISCUS criteria but as PIMs regardless of daily dose in 2012 version of Beers criteria.</p